ClinicaliQ Trial Snapshot
- A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer — Active Not Recruiting • Phase I • Oncology • NCT04577833.
- This trial compares different formulations of niraparib and abiraterone acetate to ensure they work similarly in men with advanced prostate cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and abiraterone acetate (AA) at steady state under modified fasted conditions in participants with metastatic castration-resistant prostate cancer (mCRPC). Conditions: Prostatic Neoplasms Interventions: Niraparib, Abiraterone Acetate (AA), Prednisone Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 136 participants